title: Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
abstract: Obesity is an established risk and progression factor for postmenopausal breast cancer. Interventions to decrease caloric intake and/or increase energy expenditure beneficially impact tumor progression in normoweight humans and animal models. However, despite the increasingly high global prevalence of obesity, the effects and underlying mechanisms of these energy balance modulating interventions are poorly characterized in obese individuals. The goal of this study was to better characterize the mechanism(s) responsible for the link between energy balance and breast cancer progression in the postmenopausal obesity context. We compared the effects of calorie restriction (CR), treadmill exercise (EX), and mammalian target of rapamycin (mTOR inhibitor) treatment on body composition, serum biomarkers, cellular signaling, and mammary tumor growth in obese mice. Ovariectomized C57BL/6 mice were administered a diet-induced obesity regimen for 8 weeks, then randomized into three treatment groups: control (semipurified diet fed ad libitum, maintained the obese state); 30% CR (isonutrient relative to control except 30% reduction in carbohydrate calories); and EX (control diet fed ad libitum plus treadmill exercise). Mice were implanted with syngeneic MMTV-Wnt-1 mammary tumor cells at week 12. Rapamycin treatment (5  mg/kg every 48  h) started at week 14. Tumors were excised at week 18. CR and rapamycin (but not EX) significantly reduced final tumor weight compared to control. In follow-up analysis, constitutive activation of mTOR ablated the inhibitory effects of CR on Wnt-1 mammary tumor growth. We conclude that mTOR inhibition may be a pharmacologic strategy to mimic the anticancer effects of CR and break the obesity-breast cancer progression link.
authors.affiliation: Institute of Cell and Molecular Biology, University of Texas at Austin, Austin, Texas 78712, USA.
authors.forename: Leticia M
authors.initials: LM
authors.lastname: Nogueira
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Dunlap
authors.forename: Nikki A
authors.initials: NA
authors.lastname: Ford
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Hursting
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D015153:Blotting, Western; D031204:Caloric Restriction; D002453:Cell Cycle; D049109:Cell Proliferation; D004195:Disease Models, Animal; D002149:Energy Intake; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D010052:Ovariectomy; D010805:Physical Conditioning, Animal; D017698:Postmenopause; D020123:Sirolimus / Q000627:therapeutic use*; D015996:Survival Rate; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D051155:Wnt1 Protein / Q000235:genetics*
chemical_list: D000903:Antibiotics, Antineoplastic; D051155:Wnt1 Protein; C546843:mTOR protein, mouse; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus